Levin Capital Strategies L.P. Sells 81,750 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Levin Capital Strategies L.P. cut its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 61.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 52,250 shares of the company’s stock after selling 81,750 shares during the period. Levin Capital Strategies L.P.’s holdings in ARS Pharmaceuticals were worth $286,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Nisa Investment Advisors LLC raised its position in ARS Pharmaceuticals by 22,300.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 5,600 shares of the company’s stock worth $31,000 after acquiring an additional 5,575 shares during the period. Bank of New York Mellon Corp increased its stake in shares of ARS Pharmaceuticals by 9.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 83,924 shares of the company’s stock worth $317,000 after purchasing an additional 7,024 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of ARS Pharmaceuticals by 352.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,105 shares of the company’s stock worth $61,000 after purchasing an additional 8,652 shares during the period. Letko Brosseau & Associates Inc. purchased a new position in ARS Pharmaceuticals in the third quarter valued at approximately $136,000. Finally, Denali Advisors LLC purchased a new stake in ARS Pharmaceuticals in the fourth quarter worth $480,000. Institutional investors own 68.16% of the company’s stock.

Insider Transactions at ARS Pharmaceuticals

In related news, insider Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $9.28, for a total transaction of $928,000.00. Following the transaction, the insider now directly owns 1,647,447 shares of the company’s stock, valued at $15,288,308.16. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, Director Ra Capital Management, L.P. bought 505,954 shares of the business’s stock in a transaction that occurred on Wednesday, March 27th. The shares were purchased at an average cost of $9.79 per share, for a total transaction of $4,953,289.66. Following the completion of the purchase, the director now owns 9,958,073 shares of the company’s stock, valued at $97,489,534.67. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Sarina Tanimoto sold 100,000 shares of the firm’s stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $9.28, for a total transaction of $928,000.00. Following the completion of the sale, the insider now owns 1,647,447 shares in the company, valued at $15,288,308.16. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 503,260 shares of company stock worth $4,612,480. Insiders own 35.60% of the company’s stock.

ARS Pharmaceuticals Stock Up 3.1 %

SPRY stock traded up $0.29 during trading on Friday, reaching $9.75. The company’s stock had a trading volume of 364,083 shares, compared to its average volume of 606,480. The company’s fifty day moving average is $8.99 and its 200-day moving average is $6.57. The company has a market capitalization of $944.68 million, a P/E ratio of -17.11 and a beta of 0.88. ARS Pharmaceuticals, Inc. has a 1 year low of $2.55 and a 1 year high of $11.27.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its earnings results on Thursday, March 21st. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.07. Analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.69 earnings per share for the current year.

Analyst Upgrades and Downgrades

SPRY has been the topic of a number of recent research reports. Wedbush reaffirmed an “outperform” rating and set a $19.00 price target on shares of ARS Pharmaceuticals in a research report on Monday, March 11th. Leerink Partnrs raised shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 5th. SVB Leerink upgraded ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the company from $6.00 to $18.00 in a report on Tuesday, March 5th. Finally, William Blair raised ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 20th.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.